Combination of sunitinib and anti-CD40 monoclonal antibody treatment increases the expression of ICAM-1 and VCAM-1 on tumor endothelial cells, enhancing intratumoral infiltration of CD8+ cytotoxic T cells [52]. This evidence concerns the gene CD8A and neoplasm.